LoveYourBrain Yoga for Multiple Sclerosis
4 de fevereiro de 2020 atualizado por: Andrew D. Smith III, Dartmouth-Hitchcock Medical Center
The Acceptability, Feasibility, and Impact of a Group-based Yoga and Psychoeducation Program for Community-dwelling Adults With Multiple Sclerosis: A Randomized, Cross-over Pilot Study
The purpose of the study is to assess the feasibility of a 6-week yoga and meditation intervention for people with multiple sclerosis (MS).
The study will evaluate the impact of the program on fatigue, anxiety, depression, positive affect, and other measures.
A sub-study will collect brain images using MRI on 2 subjects before and after the intervention to identify potential biological markers of MS related-fatigue.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
This study will recruit 20 subjects with multiple sclerosis (MS) to participate in a 6-week yoga/meditation program.
Subjects will be randomly assigned to one of two groups.
The first group will complete the yoga/meditation classes, followed by a waiting period.
The second group will go through a waiting period, followed by yoga/meditation classes.
Two subjects assigned to classes during the first session will be selected to participate in an MRI sub-study to look for biomarkers of MS-associated fatigue.
All subjects will complete questionnaires and assessments during 3 clinic visits - at baseline, in between the class sessions, and at the end of the study.
Questionnaires will also be mailed to subjects 6 weeks after the last study visit.
Tipo de estudo
Intervencional
Inscrição (Real)
15
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth-Hitchcock Medical Center
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Diagnosis of Multiple Sclerosis with EDSS score equal to or less than 6 (within last year)
- 18 years of age or older
- Ability to ambulate without assistance from a device or person
- Subjects taking medications for depression, fatigue, or anxiety must be stable for 8 weeks prior to baseline
- Able to read, write, and speak English
- Willing to refrain from participating in yoga or meditation outside of the study for the duration of enrollment
- Willing and able to give informed consent
Exclusion Criteria:
- Participation in yoga and/or meditation more than twice within 8 weeks prior to baseline.
- MS symptom exacerbation in the 8 weeks before baseline or other serious medical conditions that would impair ability to participate in the study.
- Any other reason that, in the investigator's opinion, would exclude the subject from participation in the study.
- Contraindication to scanning, including but not limited to ferromagnetic metal in the body, claustrophobia, inability to lie still or otherwise tolerate being in the scanner.
- Pregnant women must be excluded from the imaging component of the study due to unknown but possible risk of fetal exposure to the scanner. Women of child-bearing potential will take a confidential pregnancy test immediately prior to each scan session.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Yoga/meditation
A 6-week yoga/meditation intervention.
|
A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions.
This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
|
|
Sem intervenção: Wait list
A wait list control period.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Feasibility of conducting a yoga intervention study
Prazo: At the clinic visit immediately following the yoga class session
|
The feasibility will be determined by the completion rates of the intervention.
If fewer than 50% of subjects complete the intervention, it will be deemed unfeasible in the current format.
|
At the clinic visit immediately following the yoga class session
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in subject self-rated fatigue
Prazo: Through study completion, approximately 22 weeks
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue scale for MS: 8-item measure of fatigue.
Scale range 8 to 40.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated self-efficacy
Prazo: Through study completion, approximately 22 weeks
|
Liverpool Self-efficacy scale: 17-item measure of self-efficacy.
Scale range 17 to 68.
A higher score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated anxiety
Prazo: Through study completion, approximately 22 weeks
|
Neuro-Quality of Life (QOL) v1.0 Anxiety - Short Form: 8-item measure of anxiety.
Scale range 8 to 40.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated depression
Prazo: Through study completion, approximately 22 weeks
|
Neuro-Quality of Life (QOL) v1.0 Depression - Short Form: 8-item measure of depression.
Scale range 8 to 40.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated positive affect
Prazo: Through study completion, approximately 22 weeks
|
Neuro-Quality of Life (QOL) v1.0 Positive affect and well-being - Short form: 9-item measure of positive affect and well-being.
Scale range 8 to 48.
A higher score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject cognition/processing speed
Prazo: Through study completion, approximately 22 weeks
|
Single Digit Modalities Test: Measure of cognition/processing speed.
Score range 0 to 110.
A higher score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated sleep disturbance
Prazo: Through study completion, approximately 22 weeks
|
Neuro-QOL v1.0 Sleep disturbance - Short Form: 8-item measure of sleep disturbance.
Scale range 8 to 40.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated pain interference
Prazo: Through study completion, approximately 22 weeks
|
Patient-Reported Outcomes Measurement Information System (PROMIS) v1.0 Pain Interference - Short Form 6b: 6-item measure of sleep disturbance.
Scale range 6 to 30.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated quality of life
Prazo: Through study completion, approximately 22 weeks
|
Multiple Sclerosis Impact Scale (MSIS-29): 29-item measure of quality of life.
Scale range 29 to 145.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated cognitive function
Prazo: Through study completion, approximately 22 weeks
|
Neuro-Quality of Life (QOL) v2.0 Cognitive Function - Short Form: 8-item measure of cognitive function.
Scale range 8 to 48.
A higher score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Satisfaction rating of 6-week yoga program on a scale of 1 - 10
Prazo: At the clinic visit immediately following the yoga/meditation class session
|
Satisfaction scale: Subjects will rate their satisfaction with the yoga program on a scale of 1 - 10. Higher scores indicate a better rating.
|
At the clinic visit immediately following the yoga/meditation class session
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de julho de 2019
Conclusão Primária (Real)
30 de dezembro de 2019
Conclusão do estudo (Real)
30 de dezembro de 2019
Datas de inscrição no estudo
Enviado pela primeira vez
23 de janeiro de 2019
Enviado pela primeira vez que atendeu aos critérios de CQ
30 de janeiro de 2019
Primeira postagem (Real)
4 de fevereiro de 2019
Atualizações de registro de estudo
Última Atualização Postada (Real)
5 de fevereiro de 2020
Última atualização enviada que atendeu aos critérios de controle de qualidade
4 de fevereiro de 2020
Última verificação
1 de fevereiro de 2020
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- D19058
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .